FDA grants Priority Review for Apellis' pegcetacoplan to treat geographic atrophy; PDUFA Nov 26, 2022

Apellis Pharmaceuticals, Inc.

FDA accepted and granted Priority Review for intravitreal pegcetacoplan NDA for geographic atrophy (GA).
PDUFA target action date set for November 26, 2022; no advisory committee meeting planned.
Apellis plans to submit marketing authorization application to European Medicines Agency in H2 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.